Gut Microbiota, Metabolome, and Body Composition Signatures of Response to Therapy in Patients with Advanced Melanoma
Authors:
- Giulia VandoniGVGiulia Vandoni
- Federica D'AmicoFederica D'Amico
- Marco FabbriniMarco Fabbrini
- Luigi MarianiLMLuigi Mariani
- Sabina SieriSSSabina Sieri
- Amanda CasiratiACAmanda Casirati
- Lorenza Di GuardoLGLorenza Di Guardo
- Michele Del VecchioMVMichele Del Vecchio
- Andrea AnichiniAAAndrea Anichini
- Roberta MortariniRMRoberta Mortarini
- Francesco SgambelluriFSFrancesco Sgambelluri
- Giuseppe CelanoGCGiuseppe Celano
Open Access
- 18 July 2023
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24 (14) , 11611
Abstract
Despite the recent breakthroughs in targeted and immunotherapy for melanoma, the overall survival rate remains low. In recent years, considerable attention has been paid to the gut microbiota and other modifiable patient factors (e.g., diet and body composition), though their role in influencing therapeutic responses has yet to be defined. Here, we characterized a cohort of 31 patients with unresectable IIIC-IV-stage cutaneous melanoma prior to initiation of targeted or first-line immunotherapy via the following methods: (i) fecal microbiome and metabolome via 16S rRNA amplicon sequencing and gas chromatography/mass spectrometry, respectively, and (ii) anthropometry, body composition, nutritional status, physical activity, biochemical parameters, and immunoprofiling. According to our data, patients subsequently classified as responders were obese (i.e., with high body mass index and high levels of total, visceral, subcutaneous, and intramuscular adipose tissue), non-sarcopenic, and enriched in certain fecal taxa (e.g., Phascolarctobacterium) and metabolites (e.g., anethole), which were potentially endowed with immunostimulatory and oncoprotective activities. On the other hand, non-response was associated with increased proportions of Streptococcus, Actinomyces, Veillonella, Dorea, Fusobacterium, higher neutrophil levels (and a higher neutrophil-to-lymphocyte ratio), and higher fecal levels of butyric acid and its esters, which also correlated with decreased survival. This exploratory study provides an integrated list of potential early prognostic biomarkers that could improve the clinical management of patients with advanced melanoma, in particular by guiding the design of adjuvant therapeutic strategies to improve treatment response and support long-term health improvement.Keywords
Funding Information
- IRCCS Istituto Nazionale dei Tumori Ricerca finalizzata 2018
- SINPE 2018
This publication has 67 references indexed in Scilit:
- Italian mediterranean index and risk of colorectal cancer in the Italian section of the EPIC cohortInternational Journal of Cancer, 2012
- PANDAseq: paired-end assembler for illumina sequencesBMC Bioinformatics, 2012
- Validity of the international physical activity questionnaire short form (IPAQ-SF): A systematic reviewInternational Journal of Behavioral Nutrition and Physical Activity, 2011
- Sarcopenia as a Prognostic Factor among Patients with Stage III MelanomaAnnals of Surgical Oncology, 2011
- Search and clustering orders of magnitude faster than BLASTBioinformatics, 2010
- A practical and precise approach to quantification of body composition in cancer patients using computed tomography images acquired during routine careApplied Physiology, Nutrition, and Metabolism, 2008
- Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based studyThe Lancet Oncology, 2008
- Cytoscape: A Software Environment for Integrated Models of Biomolecular Interaction NetworksGenome Research, 2003
- Relative validity and reproducibility of a food frequency dietary questionnaire for use in the Italian EPIC centresInternational Journal of Epidemiology, 1997
- Difference in Leptin mRNA Levels Between Omental and Subcutaneous Abdominal Adipose Tissue From Obese HumansHormone and Metabolic Research, 1996